Search

Search Constraints

You searched for: Author/Creator Forster, Martin

Search Results

1. 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). (10th December 2020)

2. 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). (9th November 2020)

4. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Issue 6 (June 2022)

7. A comparison of Bayesian and non-linear regression methods for robust estimation of pharmacokinetics in DCE-MRI and how it affects cancer diagnosis. (March 2017)

8. CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in non-small cell lung cancer (NSCLC). (March 2022)

9. SARON: stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer (NSCLC). (March 2022)

10. Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: results from the VISION study and local UK experience. (March 2022)